RCT 260 patients in India, 130 treated with aspirin, promethazine, vitamin C, D, B3, zinc, and selenium, showing faster recovery with treatment. There was no hospitalization, ICU admission, or supplemental oxygen requirements in either group.
|
risk of no recovery, 89.2% lower, RR 0.11, p = 0.05, treatment 0 of 99 (0.0%), control 4 of 93 (4.3%), NNT 23, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 10, dyspnea.
|
|
risk of no recovery, 95.4% lower, RR 0.05, p < 0.001, treatment 0 of 99 (0.0%), control 10 of 93 (10.8%), NNT 9.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 10, anosmia.
|
|
risk of no recovery, 94.3% lower, RR 0.06, p = 0.003, treatment 0 of 99 (0.0%), control 8 of 93 (8.6%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 10, fatigue.
|
|
risk of no recovery, 387.9% higher, RR 4.88, p = 0.50, treatment 2 of 99 (2.0%), control 0 of 93 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 10, myalgia.
|
|
risk of no recovery, 193.9% higher, RR 2.94, p = 1.00, treatment 1 of 99 (1.0%), control 0 of 93 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 10, headache.
|
|
risk of no recovery, 8.5% lower, RR 0.91, p = 0.66, treatment 37 of 99 (37.4%), control 38 of 93 (40.9%), NNT 29, day 10, cough.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Kumar et al., 30 May 2022, Randomized Controlled Trial, India, peer-reviewed, mean age 36.0, 8 authors, study period December 2021 - February 2022, this trial uses multiple treatments in the treatment arm (combined with aspirin, promethazine, vitamin D, B3, zinc, and selenium) - results of individual treatments may vary, trial
CTRI/2021/06/034254.
Contact:
vgvclinical@gmail.com.
Efficacy and Safety of Aspirin, Promethazine, and Micronutrients for Rapid Clinical Recovery in Mild to Moderate COVID-19 Patients: A Randomized Controlled Clinical Trial
Dr. G Sunil Kumar, Dr. Atul Vadgaonkar, Dr. Srilata Purunaik, Rohit Shelatkar, Vidyadhar G Vaidya, Dr. Gayatri Ganu, Dr. Aditya Vadgaonkar, Shashank Joshi
Cureus, doi:10.7759/cureus.25467
Introduction In the present study, the combination of two tablets, one with Aspirin and Promethazine and the other with vitamin D3, C, and B3 along with zinc and selenium supplementation was proposed as an intervention (APMV2020). The ingredients in the formulation represent a precise, tailored therapy for the symptoms of COVID-19, combined with natural constituents to help the body itself build immunity to recover from infection. The present study was conducted to clinically validate the safety and efficacy of the APMV2020 tablets.
Trial design The present trial is a randomized, multicentric, controlled clinical trial involving 260 mild to moderate COVID-19 patients. The treatment duration was of 10 days.
Methodology The subjects were randomized to receive either the control intervention (clinical management protocol for COVID-19 advocated by the Indian Council of Medical Research (ICMR) or the test intervention (treatment with APMV2020 tablets along with the standard control treatment. The assessment days were baseline, days five and 10.
Results APMV2020 significantly (<0.05) improved symptoms of COVID-19 like cough, myalgia, headache, and anosmia as compared to the control group. APMV2020 treatment also reduced inflammatory markers like lactate dehydrogenase (LDH), ferritin, and C-reactive protein (CRP).
Conclusion APMV2020 can prove as a good candidate to be integrated into the COVID-19 management protocol. As it can offer speedy clinical recovery to reduce the burden on healthcare infrastructure, second, the combination shows significant anti-inflammatory potential to improve prognosis, and lastly, the immunomodulatory properties offer long-term protection that can help in combating long COVID symptoms and complications.
Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. Royal Pune Independent Ethics Committee, Pune, Maharashtra. issued approval CTRI/2021/06/034254. The study was approved by the Institutional ethics committee, Lokmanya Medical Research Centre, and Royal Pune Independent Ethics Committee and was registered with the Clinical Trial Registry of India (CTRI/2021/06/034254). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of
References
Banoun, Evolution of SARS-CoV-2: review of mutations, role of the host immune system, Nephron,
doi:10.1159/000515417Becerra-Flores, Cardozo, SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate, Int J Clin Pract,
doi:10.1111/ijcp.13525Cantisani, Ricci, Grieco, Paolino, Faina et al., Topical promethazine side effects: our experience and review of the literature, Biomed Res Int,
doi:10.1155/2013/151509Carr, Rowe, The emerging role of vitamin C in the prevention and treatment of COVID-19, Nutrients,
doi:10.3390/nu12113286Chinni, El-Khoury, Perera, Zinc supplementation as an adjunct therapy for COVID-19: challenges and opportunities, Br J Clin Pharmacol,
doi:10.1111/bcp.14826Chow, Khanna, Kethireddy, Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019, Anesth Analg,
doi:10.1213/ANE.0000000000005292Lotfi, Akbarzadeh-Khiavi, Lotfi, Micronutrient therapy and effective immune response: a promising approach for management of COVID-19, Infection,
doi:10.1007/s15010-021-01644-3Mahmud, Rahman, Rassel, Monayem, Sayeed et al., Post-COVID-19 syndrome among symptomatic COVID-19 patients: a prospective cohort study in a tertiary care center of Bangladesh, PLoS One,
doi:10.1371/journal.pone.0249644Name, Souza, Vasconcelos, Prado, Pereira et al., perspectives for COVID-19 with a focus on physical tissue barrier integrity, Front Nutr,
doi:10.3389/fnut.2020.606398Osuchowski, Winkler, Skirecki, It can be concluded that APMV2020 treatment for COVID-19 patients provides advantages over the standard of care treatment alone. There was a faster recovery of subjects from COVID-19 symptoms, along with a significant reduction in inflammatory markers like LDH ferritin, and CRP. This study serves as preliminary evidence for further research using aspirin, promethazine, vitamin D, C, and micronutrient therapy as an intervention in the management of long COVID symptoms, Lancet Respir Med,
doi:10.1016/S2213-2600(21)00218-6Wijaya, Andhika, Huang, Purwiga, Budiman, The effects of aspirin on the outcome of COVID-19: a systematic review and meta-analysis, Clin Epidemiol Glob Health,
doi:10.1016/j.cegh.2021.100883
